


Biotechnology Market Leading Key Players: Sanofi, Biogen, Abbott Laboratories and Pfizer, Inc.

Biotechnology Market was valued at USD 1023.8 Bn in 2023, this market is registering the highest CAGR of 14%, reaching USD 3672.9 Bn by 2032.

NEW YORK, NY, UNITED STATES, January 22, 2025 /EINPresswire.com/ --The <u>Global Biotechnology Market Size</u> was valued at USD 1023.8 billion in 2022, with projections showing it could reach USD 3672.9 billion by 2032. This sector is anticipated to grow at a compound annual growth rate (CAGR) of 14% from 2023 to 2032. Such growth



is driven by its significant economic impact, supporting nearly 2.3 million jobs and generating over \$3 trillion in economic output in the U.S. alone. This demonstrates the industry's crucial role in job creation and its potential to drive broader economic expansion during global challenges.

٢٢


DNA sequencing dominated technology usage with a 42.6% market share, pivotal in areas like drug discovery and genetic testing." *Tajammul Pangarkar* Advancements in biotechnology, especially through synthetic biology and gene editing technologies like CRISPR, are revolutionizing healthcare. These innovations facilitate the development of new treatments and therapies, including biofuels and drugs, transforming disease management and patient care. Additionally, the integration of AI, such as AlphaFold for predicting protein structures, is accelerating research and the discovery of

new therapeutically relevant compounds.

The sector benefits significantly from supportive government policies and investments. Initiatives like technology transfer offices, funding for cutting-edge research and development, and support for biotech incubators play pivotal roles. These efforts aid the commercialization of academic research and bolster startups, creating a nurturing environment for innovations to thrive.

Despite its rapid growth, the biotechnology sector faces challenges, including the need for substantial initial funding and navigating complex regulatory environments. The industry's shift towards de-vertical integration and global collaboration presents new opportunities. Strategic alliances and licensing deals help bridge funding gaps and accelerate product development cycles, enhancing market presence and innovation capacity. This positions biotechnology as a key player in addressing global health challenges.

Get Sample PDF Report: <u>https://market.us/report/biotechnolog</u> <u>y-market/request-sample/</u>



Key Takeaway

• The biotechnology market was valued

at \$1023.8 billion in 2022 and is expected to grow at a 14% CAGR, reaching \$3672.9 billion by 2032.

• Instruments were the most lucrative product segment in 2022, accounting for 61.5% of the market, essential in research and product development.

• Reagents and services are projected to see significant growth due to increased outsourcing of R&D and demand for advanced management tools.

• DNA sequencing was the dominant technology in 2022, with a 42.6% share, widely used in drug discovery, personalized medicine, and agriculture.

• Tissue engineering and regeneration is the fastest-growing technology segment, driven by advancements in genomics, with a projected CAGR of 13.2%.

• The healthcare application led the market in 2022, making up 35.8% of total revenue, fueled by the rising demand for personalized and cost-effective treatments.

• The food and agriculture sector is expected to grow rapidly due to increasing global population and advances in biotechnology in food processing.

• Pharmaceutical and biotechnology companies were the primary end-users in 2022, focusing on personalized medicine to drive growth at a CAGR of 13.8%.

• Contract research organizations are expanding quickly, offering flexible drug development models, with a growth rate of 13.3%.

• North America held the largest revenue share in 2022 at 39.4%, supported by a strong research

infrastructure and advanced technology.

• Asia Pacific is projected as the fastest-growing region, driven by increased healthcare demands and R&D investments, especially in China and India.

• Growing demand for personalized medicine, increased R&D investment, and the prevalence of chronic diseases are key market drivers.

• Competition from established products, lack of public awareness, ethical concerns, and high development costs pose challenges to growth.

• Opportunities for expansion exist in sustainable agriculture practices, collaboration and partnerships, and advancements in personalized medicine.

• Emerging trends shaping the market include artificial intelligence, synthetic biology, gene editing, and advancements in cell and gene therapies, and plant biotechnology.

Segmentation Analysis

The Biotechnology market is categorized into instruments, reagents and services, and software. The instruments segment leads with a substantial revenue share of 61.5% in 2022, fueled by a 13.5% CAGR. These instruments are crucial for conducting experiments and producing biotech products. The reagents and services segment, though smaller with a 27.7% share in 2022, is the fastest-growing, propelled by an increased trend in outsourcing R&D and the need for sophisticated management tools.

In terms of technology within the Biotechnology sector, DNA sequencing dominates with a 42.6% market share and a 13.8% CAGR in 2022. This segment benefits from its broad applications across drug discovery, personalized medicine, and agricultural biotechnology. Meanwhile, tissue engineering and regeneration technology is emerging rapidly, expected to grow at a CAGR of 13.2%, driven by advances in personalized medicine and genomics.

The healthcare segment is the largest in the Biotechnology market, capturing 35.8% of the revenue in 2022 with a growth rate of 13.8%. This growth is primarily due to increasing demands for personalized medicine and the rising prevalence of chronic diseases which require cost-effective treatments. Conversely, the food and agriculture sector is also expanding swiftly, expected to grow at a 13.2% CAGR due to growing global food demands and the push for sustainable agricultural practices.

Among the end-users, pharmaceutical and biotechnology companies hold a significant 49.3% market share with a 13.8% growth rate, owing to the high demand for personalized medicine and cost-effective treatment. Contract research organizations (CROs) are also gaining momentum with a market share of 25%, growing at a CAGR of 13.3%. This increase is driven by the rising outsourcing of drug development services, offering a scalable solution for pharmaceutical advancements.

Based on Technology

- Nanobiotechnology
- Tissue Engineering & Regeneration

- DNA Sequencing
- Cell-based Assays
- Fermentation
- PCR Technology
- Chromatography
- Other Technology

Based on Application

- Healthcare
- Food & Agriculture
- Natural Resources & Environment
- Industrial Processing
- Bioinformatics
- Other Applications

Based on End-User

- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
- Other End-Users

Regional Analysis

In 2022, North America emerged as the leading region in the global biotechnology market, capturing a significant 39.4% share. This region is anticipated to grow at a robust annual rate of 14.1% over the forecast period. The growth is fueled by North America's advanced research infrastructure, which includes highly skilled researchers and a supportive regulatory environment. This facilitates the development and commercialization of innovative biotechnological products.

Asia Pacific is poised to be the fastest-growing region in the biotechnology market, with a projected CAGR of 13.5%. The market's expansion in this region is driven by an increasing demand for healthcare services, supported by significant investments in research and development by local governments. Countries like China and India, with their large populations, are central to this growth, intensifying the demand for healthcare products and services.

The financial backing and technological advancements in North America, coupled with the emerging market dynamics in Asia Pacific, underscore a diverse and evolving biotechnology landscape. This positions both regions as critical to the future of biotechnology, with North America leading in innovation and APAC rapidly expanding its capabilities in the sector.

Buy Directly: <u>https://market.us/purchase-report/?report_id=65847</u>

Market Players Analysis

Emerging biotechnology companies are driving innovation across various therapeutic areas. Amgen Inc., with a market share of approximately 5.5%, specializes in biological drugs for treating bone disorders, cancer, and inflammatory diseases. Novo Nordisk A/S, holding around 5.1% of the market, focuses on diabetes medication. Meanwhile, Gilead Sciences Inc. is known for its treatments for hepatitis, viral infections, and HIV. Biogen Inc. targets neurological conditions such as multiple sclerosis and Alzheimer's disease, contributing significantly to the sector's growth.

Key players in the biotech industry include AstraZeneca, Bristol-Myers Squibb, and Sanofi, renowned for their robust drug portfolios and research initiatives. Other major contributors are Abbott Laboratories and Pfizer, Inc., which have made significant advancements in various medical fields. Companies like Merck KGaA and Johnson & Johnson Services, Inc. continue to expand their reach in global healthcare, influencing market trends and treatment pathways.

Additional influential companies in the biotech sector include Novartis AG and Hoffmann-La Roche Ltd., which lead in innovation and therapeutic development. The list also features Danaher and BD, known for their medical technologies and diagnostics solutions. Companies like Bio-Rad Laboratories Inc., General Electric, and Siemens also play critical roles in advancing biotechnological research and developing new medical technologies, ensuring continuous growth and innovation in the field.

The Primary Entities Identified In This Report Are:

- AstraZeneca
- Gilead Sciences Inc.
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Abbott Laboratories
- Pfizer Inc.
- Amgen Inc.
- Novo Nordisk A/S
- Merck KGaA
- Johnson & Johnson Services Inc.
- Novartis AG
- Hoffmann-La Roche Ltd.
- Abbott
- Agilent Technologies Inc.
- Danaher
- BD
- Bio-Rad Laboratories Inc.
- General Electric
- bioMérieux SA

- LONZA
- Hoefer Inc.
- PerkinElmer Inc.
- Promega Corporation
- Quality Biological
- Siemens
- Bio-Techne
- TAKARA HOLDINGS INC.
- Sysmex Corporation
- Tosoh Corporation
- Ortho Clinical Diagnostics
- Olympus Corporation
- Other Key Players

*We offer customized market research reports tailored to meet your specific business needs and requirements.

Get More Related Reports: Red Biotechnology Market: <u>https://market.us/report/red-biotechnology-market/</u> Al in Biotechnology Market: <u>https://market.us/report/ai-in-biotechnology-market/</u>

Biotechnology Instruments Market: <u>https://market.us/report/biotechnology-instruments-</u> <u>market/</u>

Lawrence John Prudour +91 91308 55334 email us here Visit us on social media: Facebook LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/779251891

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.